Page last updated: 2024-10-26

pentetic acid and Prostatic Neoplasms, Castration-Resistant

pentetic acid has been researched along with Prostatic Neoplasms, Castration-Resistant in 1 studies

Pentetic Acid: An iron chelating agent with properties like EDETIC ACID. DTPA has also been used as a chelator for other metals, such as plutonium.

Prostatic Neoplasms, Castration-Resistant: Tumors or cancer of the PROSTATE which can grow in the presence of low or residual amount of androgen hormones such as TESTOSTERONE.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Myint, ZW1
El Khouli, R1
Lemieux, B1
Yan, D1
St Clair, WH1
Liu, X1
Kunos, CA1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Single Arm Phase II Study of Bone-Targeted Sn-117m-DTPA in Symptomatic Castration Resistant Prostate Cancer With Skeletal Metastases[NCT04616547]Phase 21 participants (Actual)Interventional2021-12-18Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

1 trial available for pentetic acid and Prostatic Neoplasms, Castration-Resistant

ArticleYear
A single arm phase II study of bone-targeted Sn-117 m-DTPA in symptomatic castration-resistant prostate cancer with skeletal metastases.
    BMC cancer, 2022, Apr-15, Volume: 22, Issue:1

    Topics: Bone Neoplasms; Cancer Pain; Humans; Male; Pentetic Acid; Prospective Studies; Prostatic Neoplasms,

2022